Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Chemotherapy Plus Camrelizumab in PD-L1-negative Locally Advanced Cervical Cancer: a Multicentre, Single-arm, Phase 2 Trial

NCT06288360 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT06288360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06288360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Chemotherapy Plus Camrelizumab in PD-L1-negative Locally Advanced Cervical Cancer: a Multicentre, Single-arm, Phase 2 Trial
Lead sponsor
Tongji Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 12, 2024
Completion date
December 12, 2030
Enrollment
40 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, locally advanced cervical cancer, neoadjuvant chemoimmunotherapy, pd-l1 negative